Go Blue

Our Mission

True collaborative translational team science is the cancer research idea supported by Stand Up to Cancer (SU2C) with the American Association for Cancer Research (AACR). This SU2C initiative calls for the collaboration of the best basic science and clinical investigators joined into Dream Teams to concentrate on an area of cancer that has enormous potential to save lives. Our focus is on pancreatic cancer.

In 2010, the estimated number of new cases of pancreatic cancer in the US was 43,140 with an estimated 36,800 deaths. Worldwide it is estimated that 213,000 patients will develop pancreatic cancer and nearly all will die from the disease (1). Generally, most new cases of pancreatic cancer are advanced with extensive tumor growth, usually due to the lack of symptoms during the early stages of the disease. As a result, few patients are considered candidates for surgical resection. Patients with advanced pancreatic cancer are usually treated with chemotherapy in an effort to improve survival and alleviate symptoms. Median survival time ranges from 4 to 6 months in patients with metastatic disease. Overall, the 5-year survival rate is about 6% for all stages combined and decreases to 1.6% for patients with metastatic pancreatic cancer.

We are currently enrolling patients in cutting edge clinical trials involving combinations of targeted therapies for patients with pancreatic cancer. Our goal is to improve the one year survival rate for patients with metastatic pancreatic cancer from the current 23% to 80%.

Our Dream Team represents an exceptional collaboration of The Translational Genomics Research Institute, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Abramson Cancer Center at the University of Pennsylvania, Pancreatic Cancer Action Network, The Johns Hopkins University School of Medicine, Princeton University, University of Pennsylvania and Salk Institute for Biological Studies.

design by Translational Genomics Research Institute(TGen)
©2010 SU2C Dream Team
Cutting off the fuel supply in Pancreatic Cancers